We used data from a randomized trial of 206 men who were treated with radiation or radiation and 6 months of hormone therapy. Then we compared early markers for prostate cancer death to identify who, in that cohort, would be at risk for dying early from their prostate cancer. ...
$26,687 compared with nivolumab plus ipilimumab being the lowest at $11,011. However, the researchers noted their data was limited as they did not have real-world effectiveness data for this patient population and the single clinical trial may not be representative of this population acro...
The limits of our study are those of a real-life program outside of a clinical trial with prospective real-world data collection. There was no central imaging review assessing tumor at diagnosis and its evolution under treatment, and progression-free survival after the start of ONC201 treatment...
The information and opinions contained in this presentation are provided as of the date of this presentation or the respective cut-off date in respect of the clinical trial data, are subject to change without notice and will not be updated or otherwise revised to reflect any developments, which...
A total of 117 patients in the lenvatinib plus pembrolizumab cohort and 206 patients in the sunitinib cohort went on to receive another therapy. Median time to next-line therapy was 12.2 months (range, 1.45-37.36) and 6.4 months (range, 0.39-28.52) in the lenvatinib/pembrolizum...
The information and opinions contained in this presentation are provided as of the date of this presentation or the respective cut-off date in respect of the clinical trial data, are subject to change without notice and will not be updated or otherwise revised to reflect any developments, which...
The phase 2 PONALFIL trial evaluating a ponatinib regimen shows promise for long-term survival in adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.
New Phase in Prostate Cancer Fight: Cu-SAR-bisPSMA Trial Begins Sabrina Serani April 17th 2025 Article The first patient in a phase 2 clinical trial evaluating 67Cu-SAR-bisPSMA for patients with metastatic castration-resistant prostate cancer has been dosed. ...
Up to 206 patients aged 18 years and older will be enrolled in the trial which will be conducted at multiple locations across the United States and Europe. All patients must have discontinued all prior treatments for cancer for at least 21 days or 5 half-lives and recovered from...
A total of 206 patients were enrolled on that trial between 2013 and 2014. And when we look at these patients in Part 1, they were defined to be recurrent platinum-sensitive patients.So we were looking at platinum-sensitive patients, and we split them into 3 cohorts. We looked at ...